Evidence map›Paper›PMID 35216330›Full record

ReviewInternational journal of molecular sciences2022

Potential Role of Selenium in the Treatment of Cancer and Viral Infections.

Aseel O Rataan, Sean M Geary, Yousef Zakharia, Youcef M Rustum, Aliasger K Salem

Open access · goldAbstract readReview
In one paragraph

Review in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
6.9field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 64 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Biomimetic CuJournal of nanobiotechnology · 2025
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Aseel O RataanDepartment of Pharmaceutical Sciences and Experimental Therapeutics, College of Pharmacy University of Iowa, Iowa City, IA 52242, USA.ORCID 0000-0001-9136-5504
Sean M GearyDepartment of Pharmaceutical Sciences and Experimental Therapeutics, College of Pharmacy University of Iowa, Iowa City, IA 52242, USA.
Yousef ZakhariaDepartment of Internal Medicine, Division of Hematology and Oncology, University of Iowa, Iowa City, IA 52242, USA.ORCID 0000-0001-9480-2626
Youcef M RustumDepartment of Internal Medicine, Carver College of Medicine, University of Iowa, Iowa City, IA 52242, USA.
Aliasger K SalemDepartment of Pharmaceutical Sciences and Experimental Therapeutics, College of Pharmacy University of Iowa, Iowa City, IA 52242, USA.ORCID 0000-0002-1923-6633
University of Iowa · US

Funding

Pulmonary Toxicology Facility CoreP30ES005605 · NIEHS · UNIVERSITY OF IOWA · PI Jong Sung Kim · 1990 to 2026
$40.5M
NIEHS NIH HHS P30 ES005605
6 · The paper itself

Abstract

Selenium has been extensively evaluated clinically as a chemopreventive agent with variable results depending on the type and dose of selenium used. Selenium species are now being therapeutically evaluated as modulators of drug responses rather than as directly cytotoxic agents. In addition, recent data suggest an association between selenium base-line levels in blood and survival of patients with COVID-19. The major focus of this mini review was to summarize: the pathways of selenium metabolism; the results of selenium-based chemopreventive clinical trials; the potential for using selenium metabolites as therapeutic modulators of drug responses in cancer (clear-cell renal-cell carcinoma (ccRCC) in particular); and selenium usage alone or in combination with vaccines in the treatment of patients with COVID-19. Critical therapeutic targets and the potential role of different selenium species, doses, and schedules are discussed.

Indexed as

COVID-19 Drug TreatmentAnimalsAntineoplastic AgentsCOVID-19DNA RepairDrug Resistance, NeoplasmHumansNeoplasmsNF-E2-Related Factor 2SARS-CoV-2SeleniumAntineoplastic AgentsNF-E2-Related Factor 2Seleniumcancerchemotherapydrug resistanceseleniumviral infection

Identifiers

PMID35216330
PMCPMC8879146
OpenAlexW4213206225

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.